Lucentis Improves Vision As Well As Slowing Vision Loss

Featured Article
Main Category: Eye Health / Blindness
Also Included In: Seniors / Aging;  Clinical Trials / Drug Trials
Article Date: 05 Oct 2006 - 10:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 and a half stars

4.26 (19 votes)

Healthcare Prof:4 stars

4 (3 votes)


Lucentis, a drug used to treat wet age-related macular degeneration (wet AMD) was found to not only slow down vision loss in 90% of patients, but it also helped 26% of them get some of their vision back, say Lucentis makers, Genentech, Inc.

Wet AMD is the leading cause of blindness among the elderly.

Lucentis prevents the formation of abnormal, new blood vessels in the eye. It also destroys blood vessels in the eye which have started to leak.

You can read about the latest studies in The New England Journal of Medicine (NEJM).

In one study, 716 volunteers underwent an eye chart test. They all suffered from AMD. Half the group received Lucentis injection, while the other half received a placebo injection.Two years later:

-- 90% of the Lucentis patients lost fewer than 15 letters on the eye chart test

-- 50% of the placebo patients lost fewer than 15 letters on the eye chart test

-- 26% of patients who received 0.3mg of Lucentis experienced improvement in their eyesight*

-- 33% of patients who received 0.5mg of Lucentis experienced improvement in their eyesight*

-- 4% of patients who received the placebo experienced improvement in their eyesight*

* Improvement = Being able to read 15 more letters on the eye chart test

Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, M.D., Ph.D., David M. Brown, M.D., Jeffrey S. Heier, M.D., David S. Boyer, M.D., Peter K. Kaiser, M.D., Carol Y. Chung, Ph.D., Robert Y. Kim, M.D., for the MARINA Study Group
NEJM Volume 355:1419-1431 - October 5, 2006 - Number 14
Click here to see abstract online

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown, M.D., Peter K. Kaiser, M.D., Mark Michels, M.D., Gisele Soubrane, M.D., Jeffrey S. Heier, M.D., Robert Y. Kim, M.D., Judy P. Sy, Ph.D., Susan Schneider, M.D., for the ANCHOR Study Group
NEJM Volume 355:1432-1444 - October 5, 2006 - Number 14
Click here to see abstract online

Written by: Christian Nordqvist
Editor: Medical News Today

View drug information on Lucentis.

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our eye health / blindness section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Christian Nordqvist. "Lucentis Improves Vision As Well As Slowing Vision Loss." Medical News Today. MediLexicon, Intl., 5 Oct. 2006. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/articles/53457.php>

APA
Christian Nordqvist. (2006, October 5). "Lucentis Improves Vision As Well As Slowing Vision Loss." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/articles/53457.php.

Please note: If no author information is provided, the source is cited instead.


Eye Health / Blindness

Most Popular Articles



Follow Our Eye Health News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Eye Health / Blindness Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »